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Summary: Substance concentrations of plasma Cholinesterase (EC 3.1.1.8) were measured in 94 healthy
individuals without occupational exposure to known inhibitors (six samples from each individual). Immu-
noreactive Cholinesterase substance concentrations showed an inter-individual variation corresponding to
CVtotal = 22% (mean: 5.01 mg/1, SD: 1.11 mg/1). Intra-individual variations of immunoreactive Cholinesterase
substance concentration were correlated (r = 0.36) to intra-individual variations of albumin. Estimated by a
repeated-measures analysis of variance, the observed intra-individual variation of Cholinesterase substance
concentration corresponded to CV = 8.8% (SD: 0.44 mg/1), which together with a CVerror = 6% (within and
between runs), implies a biological intra-individual variation of Cholinesterase substance concentration cor-
responding to CVintra = 6.4%. Specific catalytic activity (kU/mg immunoreactive Cholinesterase) was influenced
by the ChE-1 phenotype (phenotype U: 1.58 kU/mg, phenotype UA: 1.22 kU/mg), but not by body weight,
height, age, and sex. Observed intra-individual variation of specific catalytic activity corresponded to 6.4%
(SD: 0.10kU/mg), which together with an estimated CVerror = 6.2% implies the biological intra-individual
variations of specific catalytic Cholinesterase activity to be insignificant. The insignificant CVintra makes specific
catalytic Cholinesterase activity a rational quantity for evaluation of unexpected fluctuations of Cholinesterase
activity concentrations.
T . , .. Inter- and intra-individual variation of plasma cho-Introduction ,. . . . , , , . , .Imesterase activity concentration has been studied in
Plasma Cholinesterase (pseudocholinesterase, buty- healthy individuals (5, 10 — 14) and in patients with
rylcholinesterase, acylcholine acylhydrolase, EC chronic liver diseases (10). All studies demonstrate
3.1.1.8) occurs in blood plasma as a number of distinct substantial inter-individual variations, which are sta-
isozymes, predominantly represented by a globular, tistically related to physiological factors such as body
tetrameric (Mr: 340 000) structure (1 — 6). Biosynthesis weight, height, and sex, but also influenced by a
of the 574-amino-acid-subunit (7) is controlled by the variety of other physiological and pathological con-
ChE-1 locus (8). Recently (9), the atypical, dibucaine ditions (for review, see I.e. (4)); inter-individual vari-
resistant Cholinesterase isoform has been shown to be ations of Cholinesterase activity concentration are un-
an Asp-70 —> Gly mutation. influenced by particular electrophoretic components
(5). Four of the studies (10, 11, 13, 14) demonstrate
intra-individual variations in healthy individuals cor-
responding to a biological CVintra = 5 — 5.5%; intra-
') Cholinesterase, pseudocholinesterase, acylcholine acylhydro- individual variations of plasma Cholinesterase activity
läse (EC 3.1.1.8). . .2) The study was financially supported by Aarhus University concentration are independent of age, body weight,
Research Foundation. height, sex, or ChE-1 phenotype.
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In health surveillance programmes, a decrease of
plasma cholinesterase activity concentration in indi-
viduals who are occupationally exposed to organo-
phosphorus pesticides, may readily be interpreted an
indication of organophosphorus poisoning (15). To
decide if such individuals really have been subjects to
uncontrolled exposure, one must determine whether
the decreased catalytic cholinesterase activity concen-
tration is caused by a reduced cholinesterase substance
concentration (e. g. due to reduced synthesis), or by
a partial inhibition of the catalytic activity (e. g. due
to systemic insecticides). In such situations, and as an
alternative to measuring catalytic activity concentra-
tions before and after in vitro reactivation, compari-
sons of specific catalytic cholinesterase activities
(U/mg cholinesterase) have proved a useful diagnostic
tool (B. N. La Du, Univ. of Michigan, Ann Arbor,
personal communication).
Earlier studies indicate a close relation between cho-
linesterase activity concentration and cholinesterase
substance concentration (16). However, no systematic
studies of normal inter- and intra-individual varia-
tions of cholinesterase substance concentration (mg/1)
or specific cholinesterase activity (U/mg) have so far
been published. The aim of the present study is to
describe such inter- and intra-individual variations of
immunoreactive plasma cholinesterase substance con-
centration and specific catalytic plasma cholinesterase
activity in a healthy population group without occu-
pational exposure to known cholinesterase inhibitors;
further, the study analyses the relative influence of
five factors (ChE-1 phenotype, sex, age, body weight,
and height) on these variations; finally, the observed
variations of cholinesterase substance concentration




Consecutive values of immunoreactive plasma cholinesterase
substance concentrations, plasma cholinesterase activity con-
centrations, and plasma albumin substance concentrations (six
samples from each individual) were obtained from 94 (43 males,
51 females, aged 20 — 65 years) of 193 apparently healthy in-
dividuals earlier studied (14). Five of the 94 individuals were
of ChE-1 phenotype = UA; the remaining 89 individuals were
found to be of ChE-1 phenotype U.
Analyt ical methods
Immunoreactive cholinesterase substance concentrations were
determined by an enzyme immunoassay (16). Calibration was
standardized with a highly purified human cholinesterase,
which was quantitated according to Lowry et al. (17). Day to
day reproducibility (M + D Monitrol I-E and Monitrol II-E):
CV = 5.7% (x = 4.57 mg/1, SD = 0.26 mg/1, n = 34, lot no.
LTD 210), CV = 6.2% (x = 3.45 mg/1, SD = 0.21 mg/1, N = 44,
lot not. PTD 109).
Determination of plasma cholinesterase activity concentration
was performed at 37 °C using butyryl thiocholine as substrate.
Day to day reproducibility (M + D Monitrol I-E and Monitrol
II-E): CV = 1.34% (x = 4.38 kU/1, SD = 0.059 kU/1, N = 125,
lot no. PTD 108), CV = 1.92% (x = 6.38 kU/1, SD = 0.123
kU/1, N = 44, lot no. LTD 109), and CV = 1.36% (x = 6.51
kU/1, SD = 0.089 kU/1, N = 81, lot no. LTD 210).
Albumin substance concentration was measured by a turbidi-
metric immunoassay using a polyclonal (rabbit) anti-human
albumin (Q328, Dakopatts, Glostrup, Denmark). The calibra-
tion was standardized with a commercial protein standard
(Human Serum Protein Calibrator, lot no. 048, Dakopatts,
Glostrup, Denmark). Day to day reproducibility (Seronorm™
Human, batch no. 1200, Nycomed, Oslo, Norway): CV = 3.9%
(x = 37.8 g/1, SD = 1.49 g/l, N = 86).
Statis t ics
Stepwise multiple regressions, analyses of variance, and re-
peated-measures analyses of variance were performed on an
IBM PC/AT using the SPSS/PC + software package (SPSS Inc.,
Chicago, IL).
Results
Cholinesterase activity concentration and
cholinesterase substance concentration
Table 1 shows plasma cholinesterase substance con-
centrations (mg/1 immunoreactive cholinesterase),
cholinesterase activity concentrations (kU/1), and spe-
cific catalytic cholinesterase activities (kU/mg immu-
noreactive cholinesterase) in the 94 healthy individu-
als studies. The table shows a higher immunoreactive
cholinesterase substance concentration in individuals
of ChE-1 phenotype U than in individuals of ChE-1
phenotype UA, and a higher cholinesterase substance
concentration in males than in females. Specific cat-
alytic cholinesterase activity was uninfluenced by sex,
but significantly lower (p < 0.001) in UA individuals
than in individuals of ChE-1 phenotype U.
The possible influence of sex, age, body weight,
height, and ChE-1 phenotype on the inter-individual
variation of cholinesterase substance concentration
was analysed from a stepwise multiple regression
(y = BO + BÄ + B2X2 + + BnXn; male
= 1, female = 2, phenotype U = 1, phenotype UA
= 2). Like catalytic cholinesterase activity concentra-
tions (14), immunoreactive cholinesterase substance
concentrations are significantly influenced by body
weight, height, sex, and ChE-1 phenotype (tab. 2). Of
the five factors, only the ChE-1 phenotype (multiple
r2 = 0.739) influences the specific cholinesterase cat-
alytic activity. Table 3 shows the relative influence by
the four significant factors on the immunoreactive
cholinesterase substance concentration as assessed
from a two-way ANOVA. Of the 51 females, 7 used
oral contraceptives; the 7 women taking contraceptive
pills showed a significantly (0.01 < p < 0.05) lower
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Tab. 1. Cholinesterase activity concentration, substance concentration, and specific catalytic activity in healthy individuals, each














































Tab. 2. Major factors influencing inter-individual variations of plasma Cholinesterase substance concentration (average of six














Variable entered Multiple r
Body weight 0.421
H- Height 0.473
+ Sex (1,2) 0.525
+ ChE-type (1, 2) 0.568
+ Age 0.572











0.327 0.002 N. S.
• height + B3 · sex (1, 2) + B4 · ChE-type (1, 2)):
***: p < 0.001 *: 0.01 < p < 0.05 N. S.: not significant
Tab. 3. Analysis of variance. Relative influence of covariates, sex, and ChE-type on plasma Cholinesterase substance concentration





























































*: 0.01 < p < 0.05 **: 0.001 < p < 0.01 ***: p < 0.001
immunoreactive Cholinesterase substance concentra-
tion (x = 3.83 mg/1, SD = 0.47 mg/1) than the 44
women who did not (x = 4.79 mg/1, SD = 0.86 mg/1).
Intra-individual variations of immunoreactive Cholin-
esterase substance concentration were calculated from
the six consecutive determinations in each individual.
Like intra-individual variations of Cholinesterase ac-
tivity concentrations, the distribution of maximum
intra-individual variations of Cholinesterase substance
concentrations (differences between highest and low-
est substance concentration as a percentage of the
mean concentration) was skew to the right (mean:
21%; range 6%-43%); in 15 of the 94 healthy vol-
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Tab. 4. Repeated measures analysis of variance; tests involving observed within-subject effects. 94 individuals, six determinations
in each individual.
Source of variation
0.01 < p < 0.05













































unteers the difference between highest and lowest
immunoreactive Cholinesterase substance concentra-
tion exceeded 30%. A quantitative estimate of the
intra-individual variation was obtained from a re-
peated-measures analysis of variance. Table 4 shows
an average intra-individual variation of immunoreac-
tive Cholinesterase substance concentration corre-
sponding to SDintra = 0.44 mg/1 (CVintra = 8.8%).
Intra-individual variation of immunoreactive cholin-
esterase substance concentration was unrelated to sex
or ChE-1 phenotype. The average intra-individual
variation of catalytic Cholinesterase activity concen-
tration (CVintra = 5.6%) was the same as previously
reported (14).
Intra-individual variations of specific catalytic cholin-
esterase activity were assessed from immunoreactive
Cholinesterase substance concentrations and catalytic
Cholinesterase activity concentrations. Standard de-
viations calculated from the six determinations in each
individual varied from 0.03 to 0.21 kU/mg. Repeated-
measures analysis of variance showed an average in-
tra-individual variation corresponding to SDintra
= 0.10 kU/mg (CVintra = 6.4%), without influence
by sex or by ChE-1 phenotype.
Albumin concentration
Plasma albumin concentrations were found to be
higher (p < 0.001) in the 43 males (x: 45.8 g/l; SD:
2.55 g/1) than in the 51 females (x: 42.7 g/l; SD: 2.84
g/1); further, a stepwise multiple regression analysis
showed an influence by age (p < 0.001) and by body
weight (0.01 < p < 0.05). Women who used oral
contraceptives exhibited a significantly (p < 0.001)
lower albumin concentration (x = 40.2 g/1, SD = 1.96
g/l, N = 7) than women who did not (x = 43.1 g/1,
SD = 2.78 g/l, N = 44). Albumin concentrations were
uncorrelated to Cholinesterase substance concentra-
tions (r = 0.18).
Maximum intra-individual variations (differences be-
tween highest and lowest concentrations in percentage
of a person's mean concentration) showed a distri-
bution similar to that of Cholinesterase; mean: 16.7%;
range: 4.3%—43%. Intra-individual variations of al-
bumin concentration (expressed as CV) were corre-
lated to intra-individual variations of Cholinesterase
substance concentration (r = 0.36, p < 0.001).
Discussion
In earlier studies, the immunoreactive plasma Cholin-
esterase substance concentrations were reported to
5 — 15 mg/1 (18 — 21). The present study shows a mean
plasma immunoreactive Cholinesterase substance con-
centration of only 5 mg/1 (SD: 1.1 mg/1). Although
there are various theoretical reasons for this discrep-
ancy (for discussion, see I.e. (16)), the previously
reported Cholinesterase substance concentrations were
probably overestimated. This suggestion is supported
by comparison of the Cholinesterase substance con-
centration (16) and protein concentration (17) in a
highly purified Cholinesterase preparation (made by
Dr. O. Lockridge, Univ. of Michigan, Ann Arbor,
using affinity chromatography on procainamide se-
pharose (22) combined with ion exchange), which
showed that the immunoreactive Cholinesterase sub-
stance concentration was 0.90 of that expected from
the protein concentration.
Like Cholinesterase activity concentration, immuno-
reactive Cholinesterase substance concentration shows
a substantial inter-individual variation. The same four
factors that influence Cholinesterase activity concen-
tration (sex, body weight, height, and ChE-1 pheno-
type) influence immunoreactive Cholinesterase sub-
stance concentration (tab. 3). Recently, body weight
and height were also shown to influence alanine ami-
notransferase, aspartate aminotransferase, and γ-glu-
tamyl transferase (23). The mechanisms giving rise to
lower immunoreactive Cholinesterase substance con-
centrations in individuals of ChE-1 phenotype UA
than in matching individuals of ChE-1 phenotype U
(tab. 2) are completely unknown (increased degrada-
tion?, decreased synthesis? decreased affinity of the
monoclonal antibody to the UA isoform?). However,
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although mechanisms involved are unknown, the de-
scribed effects have to be considered, when comparing
unmatched population groups.
Individuals exhibiting large intra-individual variations
of plasma cholinesterase substance concentration also
tend to exhibit large intra-individual variations of
albumin concentration. Roughly estimated, one sev-
enth (0.362) of the observed intra-individual variance
of cholinesterase substance concentration may be ex-
plained from this relationship (parallel fluctuations of
cholinesterase and albumin synthesis/degradation?,
variations due to preanalytical errors?). Suggesting
simple additivity of variances, an average biological
CVintra can be estimated from observed CVintra and
CVerror· Even though intra-individual variations differ
from one individual to another, such estimates are
crucial in diagnostic decision-making (24), and for
defining appropriate analytical goals (25 — 26).
From the observed CVintra (8.8%) and the actual
analytical imprecision (CVerror = 6%), the biological
CVintra for cholinesterase substance concentrations
may be estimated to be 6.4%. In a similar way, the
corresponding biological CVintra for cholinesterase ac-
tivity concentration was calculated to be 5.4%; this
estimate accords with other studies (10—11, 13 — 14)
and with results obtained from studies of other plasma
enzymes (26). From the actual CVerror for catalytic
cholinesterase activity concentration and immuno-
reactive cholinesterase substance concentration, the
actual CVerror of specific catalytic activity was calcu-
lated to be 6.2%. Combined with the observed CVintra
(6.4%), this implies an insignificant (F=1.07,
p > 0.05) biological CVintra of the specific catalytic
cholinesterase activity (1.6%). Intra-individual vari-
ations of cholinesterase activity concentration in
healthy individuals are therefore due to varying cho-
linesterase substance concentrations, and not to var-
ying inhibition of the catalytic cholinesterase activity.
The insignificant CVintra makes specific catalytic cho-
linesterase activity a rational quantity for evaluation
of unexpected fluctuations of cholinesterase activity
concentrations.
Acknowledgement
The Statens Seruminstitut, Copenhagen (Department of Clini-
cal Biochemistry; head: B. N0rgaard-Pedersen) is acknowledged
for supplying the monoclonal antibody HAH 2-1 against hu-
man cholinesterase. I wish to express my gratitude to Dr. O.
Lockridge, Univ. of Michigan, Ann Arbor, USA, for giving me
access to her highly purified preparation of human cholinester-
ase.
References
1. LaMotta, R. V. & Woronick, C. L. (1971) Molecular het-
erogeneity of human serum cholinesterase. Clin. Chem. 17,
135-144.
2. Brown, S. S., Kalow, W., Pilz, W., Whittaker, M. & Wo-
ronick, C. L. (1981) The plasma cholinesterases: A new
perspective. Adv. Clin. Chem. 22, 1 — 123.
3. Mogensen, J. V. (1983) Cholinesterase and succinylcholine.
Dan. Med. Bull. 30, 129-150.
4. Whittaker, M. (1986) Cholinesterase (Beckman, L., ed.
Monographs in human genetics; vol. 11). Karger, Basel, pp.
1-132.
5. Brock, A. (1989) Additional electrophoretic components of
cholinesterase in plasma: a phenomenon of no importance
to the total plasma cholinesterase activity. J. Clin. Chem.
Clin. Biochem. 27, 429-431.
6. Lockridge, O. (1988) Structure of human serum cholines-
terase. BioEssays 9, 125-128.
7. Lockridge, O., Bartels, C. R, Vaughan, Τ. Α., Wong, C.
K., Norton, S. E. & Johnson, L. L. (1987) Complete amino
acid sequence of human serum cholinesterase. J. Biol.
Chem. 2(52, 549-557.
8. McTiernan, C., Adkins, S., Shatonnet, A., Vaughan, Τ. Α.,
Bartels, C. F., Kott, M., Rosenberry, T. L., LaDu, B. N. &
Lockridge, O. (1987) Brain cDNA clone for human
cholinesterase. Proc. Natl. Acad. Sei. 84, 6682-6686.
9. McGuire, M. C., Nogucira, C. P., Bartels, C. R, Lightstone,
H., Hajra, Α., Van der Spek, A. R L., Lockridge, O. & La
Du, B. N. (1989) Identification of the structural mutation
responsible for the dibucaine-resistant (atypical) variant
form of human serum cholinesterase. Proc. Natl. Acad. Sei.
56,953-957.
10. H lzel, W. G. E. (1987) Intra-individual variation of ana-
lytes in serum from patients with chronic liver diseases.
Clin. Chem. 33, 1133-1136.
11. Sidell, R R. & Kaminskis, A. (1975) Temporal intrapersonal
physiological variability of cholinesterase activity in human
plasma and erythrocytes. Clin. Chem. 27, 1961 — 1963.
12. Lepage, L., Schiele, R, Gueguen, R. & Siest, G. (1985)
Total cholinesterase in plasma: Biological variations and
reference limits. Clin. Chem. 31, 546 — 550.
13. Moses, G. C., Tuckerman, J. R & Henderson, A. R. (1986)
Biological variance of cholinesterase and 5'-nucleotidase in
serum of healthy persons. Clin. Chem. 32, 175 — 177.
14. Brock, A. & Brock, V. (1990) Plasma cholinesterase activity
in a healthy population group without occupational expo-
sure to known cholinesterase inhibitors: Relative influence
of some factors related to normal inter- and intra-individual
variations. Scand. J. Lab. Clin. Invest. 50, 401-408.
15. Health and Safety Executive (1986) Health surveillance of
workers exposed to organo-phosphorus and carbamate pes-
ticides. Guidance Note MS 17. Sheffield, pp. 1—4.
16. Brock, A., Mortensen, V., Loft, A. G. R. & N0rgaard-
Pedersen, B. (1990) Enzyme immunoassay of human cho-
linesterase (EC 3.1.1.8): Immunoreactive substance concen-
tration compared to catalytic activity concentration in ran-
domly selected serum samples from healthy individuals. J.
Clin. Chem. Clin. Biochem. 28, 221-224.
17. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall,
R. J. (1951) Protein measurement with the Polin phenol
reagent. J. Biol. Chem. 193, 265-275.
18. Krasilnikoff, P. A. & Weeke, B. (1971) The Intravascular
mass of 21 serum proteins in normal mature and premature
children. In: Proteins of the biological fluids, vol. 18 (Peeters,
H., ed.). Pergamon Press, Oxford, pp. 169-172.
19. Weeke, B. & Krasilnikoff, P. A. (1972) The concentration
of 21 serum proteins in normal children and adults. Acta
Med. Scand. 792, 149-155.
J. Clin. Chem. Clin. Biochem. / Vol. 28, 1990 / No. 11
856 Brock: Cholinesterase substance concentrations in a healthy population
20. Brogren, C.-H. & B0g-Hansen, T. C. (1975) Enzyme char-
acterization in quantitative immunoelectrophoresis: An en-
zymological study of human serum esterases. Scand. J.
Immunol. 4, suppl. 2, 37-51.
21. B0g-Hansen, J. C., Lorenc-Kubis, I. & Bjerrum, O. J. (1980)
Quantitative immunoelectrophoresis. A survey and some
applications. In: Electrophoresis 79 (Radola, B. J., ed.).
Walter de Gruyter and Co., Berlin, pp. 173-192.
22. Lockridge, O. & La Du, B. N. (1978) Comparison of
atypical and usual human serum cholinesterase. Purifica-
tion, number of active sites, substrate affinity, and turnover
number. J. Biol. Chem. 253, 361-366.
23. Robinson, D. & Whitehead, T. P. (1989) Effect of body
mass and other factors on serum liver enzyme levels in men
attending for well population screening. Ann. Clin.
Biochem. 26, 393-400.
24. Harris, E. K. & Yasaka, T. (1983) On the calculation of a
"reference change" for comparing two consecutive meas-
urements. Clin. Chem. 29, 25-30.
25. Fräser, C. G. (1983) Desirable performance standards for
clinical chemistry tests. Adv. Clin. Chem. 23, 299-339.
26. Fräser, C. G. (1988) The application of theoretical goals
based on biological variation data in proficiency testing.
Arch. Pathol. Lab. Med. 112, 404-415.
Axel Brock, MD, PhD
Department of Clinical Chemistry
Randers Centralsygehus
DK-8900 Randers
J. Clin. Chem. Clin. Biochem. / Vol. 28,1990 / No. 11
